Goldman Sachs
NKTR icon

Goldman Sachs’s Nektar Therapeutics NKTR Stock Holding History

Goldman Sachs’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,833
Closed -$372K – 6802
2021
Q4 		$372K Buy
1,833
+333
+22% +$72.2K ﹤0.01% 5557
2021
Q3 		$404K Sell
1,500
-500
-25% -$120K ﹤0.01% 5327
2021
Q2 		$515K Buy
+2,000
New +$554K ﹤0.01% 5197
2018
Q4 		– Sell
-1,580
Closed -$1.45M – 5526
2018
Q3 		$1.45M Buy
+1,580
New +$1.35M ﹤0.01% 3813
2018
Q1 		– Sell
-2,593
Closed -$2.32M – 6232
2017
Q4 		$2.32M Sell
2,593
-74
-3% -$43.8K ﹤0.01% 3662
2017
Q3 		$960K Hold
2,667
– – ﹤0.01% 4608
2017
Q2 		$782K Buy
+2,667
New +$771K ﹤0.01% 4692
2016
Q1 		– Sell
-473
Closed -$120K – 7239
2015
Q4 		$120K Hold
473
– – ﹤0.01% 6072
2015
Q3 		$78K Sell
473
-2,654
-85% -$469K ﹤0.01% 6614
2015
Q2 		$587K Sell
3,127
-3,806
-55% -$655K ﹤0.01% 5020
2015
Q1 		$1.14M Buy
+6,933
New +$1.42M ﹤0.01% 4323
2014
Q3 		– Sell
-2,487
Closed -$478K – 7206
2014
Q2 		$478K Buy
+2,487
New +$440K ﹤0.01% 5365
2014
Q1 		– Sell
-3,333
Closed -$568K – 6870
2013
Q4 		$568K Buy
3,333
+200
+6% +$32.3K ﹤0.01% 5207
2013
Q3 		$491K Buy
+3,133
New +$579K ﹤0.01% 5161

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs's NKTR Position: Q1 2026 in Review

Goldman Sachs reduced its Nektar Therapeutics (NKTR) stake by 14% in Q1 2026, selling an estimated $1.19M and leaving 126,942 shares worth $9.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3143.

Goldman Sachs first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $160M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Goldman Sachs held 126,942 shares of Nektar Therapeutics worth $9.13M as of Q1 2026.
  • Goldman Sachs sold 20,851 Nektar Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Nektar Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3143 holding.
  • Goldman Sachs first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Nektar Therapeutics position peaked at $160M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.